ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platformProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody for AD; PMN350, a monoclonal antibody for AD; and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing prospect therapies targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS and frontotemporal dementia, as well as alpha synuclein in Parkinson's disease and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-416-8476898
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$229.00
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Promis Neurosciences (TSE:PMN) Frequently Asked Questions
What is Promis Neurosciences' stock symbol?
Promis Neurosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PMN."
When is Promis Neurosciences' next earnings date?
Has Promis Neurosciences been receiving favorable news coverage?
Media headlines about PMN stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Promis Neurosciences earned a news impact score of -2.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Promis Neurosciences' key competitors?
Some companies that are related to Promis Neurosciences include Enochian Biosciences (ENOB), Kodiak Sciences (KOD), IMV (IMV), Monash IVF Group (MVF), ProMetic Life Sciences (PLI), OncoCyte (OCX), Emblem (EMC), Fennec Pharmaceuticals (FRX), CorMedix (CRMD), CorMedix (CRMD), BELLUS Health (BLU), Cynata Therapeutics (CYP), BioTime (BTX), BioTime (BTX) and Neuren Pharmaceuticals (NEU).
Who are Promis Neurosciences' key executives?
Promis Neurosciences' management team includes the folowing people:
- Mr. Eugene Williams, Exec. Chairman (Age 60)
- Dr. Elliot Goldstein, Pres, CEO & Director (Age 68)
- Dr. Neil R. Cashman, Founder, Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
- Mr. Daniel E. Geffken, Chief Financial Officer (Age 62)
- Dr. Johanne Kaplan, Chief Devel. Officer
How do I buy shares of Promis Neurosciences?
Shares of PMN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Promis Neurosciences' stock price today?
One share of PMN stock can currently be purchased for approximately C$0.27.
How big of a company is Promis Neurosciences?
Promis Neurosciences has a market capitalization of C$69.23 million and generates C$229.00 in revenue each year.
What is Promis Neurosciences' official website?
How can I contact Promis Neurosciences?
Promis Neurosciences' mailing address is 1920 Yonge St Suite 200, TORONTO, ON M4S 3E2, Canada. The company can be reached via phone at +1-416-8476898.
MarketBeat Community Rating for Promis Neurosciences (TSE PMN)
MarketBeat's community ratings are surveys of what our community members think about Promis Neurosciences and other stocks. Vote "Outperform" if you believe PMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
